Asian Tech Press (Nov 8) -- Chinese drugmaker Walvax (300142.SZ) announced on Tuesday that it received product registration certificates for its pneumococcal vaccines in the Philippines.

Walvax Biotechnology Co Ltd said in a statement that the 13-valent pneumococcal conjugate vaccine ("Pneumocon 13" in the Philippines) and the 23-valent pneumococcal polysaccharide vaccine ("Pneumops 23"), produced by its subsidiary Yuxi Walvax Biotechnology Co. Ltd., have recently received certificates of product registration (CPRs) from the Food and Drug Administration of the Philippines.

It said that with the certificates, future sales of the above products in the Philippines will have a positive impact on the company's subsequent operating results.

In late October, Walvax announced that its PVC13 product ("VALENINA" in Indonesia) received a marketing license from Indonesia's food and drugs agency (BPOM).